UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of March 2020
Commission
File Number 001-15170
GlaxoSmithKline plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 13 March 2020, London UK - LSE Announcement
Publication of Supplementary Prospectus
The
following supplementary prospectus dated 13 March 2020 has been
approved by the UK Listing Authority and is available for
viewing:
GlaxoSmithKline plc, GlaxoSmithKline Capital plc and GSK Capital
K.K. £20,000,000,000 Euro Medium Term Note
Programme
Copies
of the supplementary prospectus and the documents
incorporated by reference within it have been submitted to the
National Storage Mechanism and will shortly be available for
inspection at and can be downloaded from:
www.morningstar.co.uk/uk/NSM
For
further information, please contact:
GlaxoSmithKline plc
980 Great West Road
Brentford
Middlesex
TW8 9GS
United Kingdom
Enquiries:
|
UK
Media enquiries:
|
David
Mawdsley
Simon
Steel
|
(020)
8047 5564
(020)
8047 3763
|
|
European
Analyst/Investor enquiries:
|
James
Dodwell
Danielle
Smith
|
(020)
8047 2406
(020)
8047 0932
|
BASIS ON WHICH YOU MAY ACCESS THE SUPPLEMENTARY
PROSPECTUS
Please
note that the information contained in
the supplementary prospectus may be addressed to
and/or targeted at persons who are residents of
particular countries (specified in
the base prospectus) only and is not intended for use and
should not be relied upon by any person outside these countries
and/or to whom the offer contained in
the base prospectus is not addressed. Prior to
relying on the information contained in
the supplementary prospectus you must ascertain from
the base prospectus whether or not you are part of the
intended addressees of the information contained
therein.
Your
right to access this service is conditional upon complying with the
above.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GlaxoSmithKline plc
|
|
|
(Registrant)
|
|
|
|
|
Date: March
13, 2020
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GlaxoSmithKline plc
|